UBS AM’s GenMark Diagnostics, Inc GNMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-73,720
Closed -$1.76M 2812
2021
Q1
$1.76M Sell
73,720
-1,802
-2% -$33.5K ﹤0.01% 1808
2020
Q4
$1.1M Sell
75,522
-4,048
-5% -$53.7K ﹤0.01% 1940
2020
Q3
$1.13M Buy
79,570
+2,878
+4% +$44K ﹤0.01% 1790
2020
Q2
$1.13M Buy
76,692
+9,252
+14% +$94K ﹤0.01% 1741
2020
Q1
$278K Buy
67,440
+12,466
+23% +$58.4K ﹤0.01% 2180
2019
Q4
$264K Sell
54,974
-1,440
-3% -$7.94K ﹤0.01% 2399
2019
Q3
$342K Buy
56,414
+4,468
+9% +$27.9K ﹤0.01% 2409
2019
Q2
$337K Buy
51,946
+9,519
+22% +$67.1K ﹤0.01% 2372
2019
Q1
$301K Sell
42,427
-20,053
-32% -$132K ﹤0.01% 2314
2018
Q4
$304K Hold
62,480
﹤0.01% 2213
2018
Q3
$459K Sell
62,480
-5,807
-9% -$42.6K ﹤0.01% 2123
2018
Q2
$436K Buy
68,287
+18,887
+38% +$125K ﹤0.01% 2155
2018
Q1
$269K Hold
49,400
﹤0.01% 2258
2017
Q4
$206K Buy
49,400
+26,000
+111% +$156K ﹤0.01% 2305
2017
Q3
$225K Hold
23,400
﹤0.01% 2200
2017
Q2
$277K Buy
+23,400
New +$299K ﹤0.01% 2074
2016
Q4
Sell
-20,400
Closed -$241K 2744
2016
Q3
$241K Buy
20,400
+6,300
+45% +$60.8K ﹤0.01% 2373
2016
Q2
$123K Hold
14,100
﹤0.01% 2561
2016
Q1
$74K Hold
14,100
﹤0.01% 2595
2015
Q4
$109K Hold
14,100
﹤0.01% 2651
2015
Q3
$111K Hold
14,100
﹤0.01% 2600
2015
Q2
$128K Hold
14,100
﹤0.01% 2651
2015
Q1
$183K Buy
14,100
+700
+5% +$9.15K ﹤0.01% 2512
2014
Q4
$182K Hold
13,400
﹤0.01% 2501
2014
Q3
$120K Hold
13,400
﹤0.01% 2484
2014
Q2
$181K Buy
+13,400
New +$140K ﹤0.01% 2435

UBS AM's GNMK Position: Q2 2021 in Review

UBS AM sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 73,720 shares — an estimated $1.76M sold.

UBS AM first reported a position in GNMK in Q2 2014 and held it in 26 quarters. The position peaked at $1.76M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

  • UBS AM reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 73,720 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.76M.
  • UBS AM first reported a position in GenMark Diagnostics, Inc in Q2 2014 and held it in 26 quarters.
  • UBS AM's GenMark Diagnostics, Inc position peaked at $1.76M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.